News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<IPO>Legend Biotech Plans to List in HK as Early as This Yr, Raising at Least US$300M: Wire
Legend Biotech (LEGN.US), a joint venture of GENSCRIPT BIO (01548.HK), planned to list in Hong Kong as early as this year, aiming to raise US$300-400 million, according to IFR.Lege...
Reset
Send
The window will close in 5 seconds
<IPO>Legend Biotech Plans to List in HK as Early as This Yr, Raising at Least US$300M: Wire
Close
Recommend
15
Positive
19
Negative
15
 
SHORT SELL
 
STOCK INFO
aacat by AASTOCKS
Open a new trading account to get NVDA share!

Legend Biotech (LEGN.US)      , a joint venture of GENSCRIPT BIO (01548.HK)  +0.510 (+4.304%)    Short selling $24.12M; Ratio 40.565%   , planned to list in Hong Kong as early as this year, aiming to raise US$300-400 million, according to IFR.

Legend Biotech was founded in 2014 and is the world's largest standalone cell therapy company, according to the Company's website.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-02 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

Related News M Stanley: S&P 500 Adjustment Nearing End; 'Magnificent Seven' in US Stocks Very Attractive in Valuation

AASTOCKS Financial News
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.